PlatinumLED

PlatinumLED is the red and near-infrared light therapy brand of Platinum LED Holdings LLC of Lake Mary, Florida, run by its founders Mark and Michelle Sawyer, which says it began in grow lights and moved to light therapy for people in 2015 and 2016. FDA’s registration lists the company as developing specifications rather than manufacturing; its panels are made by contract manufacturers in Asia, among them E.Shine Systems Limited of China, which lists the BIOMAX and BIOMAX PRO under its own FDA registration. It sells direct from platinumtherapylights.com.

Intertek’s directory lists the BIOMAX and BIOMAX PRO panels to ES60601-1, the US edition of the IEC 60601-1 medical electrical safety standard: ETL Classified on the BIOMAX sizes and the PRO NANO and MIDI, and ETL Listed on the PRO GRANDE and ULTRA. No PlatinumLED device has a 510(k), and the SaunaMAX PRO, the BIO series and the BIOMAX GO carry no safety listing. Light Therapy Insiders, a market-wide tester that receives PlatinumLED units and commission, measured the PRO ULTRA at 101 mW/cm2 averaged at 6 inches; PlatinumLED states figures near 300 from a solar meter, and the LightLab reports it commissions average only the central 6 by 6 inches of each panel.

The eight PlatinumLED devices compared here run on platinumtherapylights.com from $299 for the BIOMAX GO to $1,599 for the BIOMAX PRO ULTRA, and PlatinumLED is clearing the BIO series. It also sells the BIOMAX panels from $659 to $1,299, the BIORevive laser and LED helmets at $659 and $1,299, and the StudioMAX ceiling fixture for commercial installations. Every device carries a 3-year warranty for its original buyer, and LED panels may be returned within 60 days less a 20 percent restocking fee and return shipping.

PlatinumLED holds 4.0 from 198 Trustpilot reviews, having claimed the profile in October 2025, with 61 percent five-star against 32 percent one-star in September 2026, and the BBB rates its three files F, F and C. Amazon US carries only PlatinumLED’s link-out listings for multi-panel sets, no US retailer sells its devices with a review file of their own, and FDA’s adverse-event database holds two injury reports on the BIOMAX 900, from 2022 and 2026.